Press release
Illumina's Board of Directors elects two experienced Independent Directors to Board
Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina's Board Scott B. Ullem, CFO of Edwards Lifesciences, also named to Board SAN DIEGO,
About this update from Illumina, Inc.
[{"type":"text","content":"Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina's Board\nScott B. Ullem, CFO of Edwards Lifesciences, also named to Board \nSAN DIEGO, June 2, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes consistent with the goal of enhancing long-term shareholder value.\nThe Board has elected two new independent board members to join the board immediately. The first, Stephen P. MacMillan, Chairman, President and Chief Executive Officer of Hologic, a medical device and diagnostic manufacturer, will become an independent director and non-executive Chair of Illumina's board. The second, Scott B. Ullem, Corporate Vice President and Chief Financial Officer of Edwards Lifesciences, a global leader in patient-focused innovations for structural heart disease and critical care monitoring, will be an independent director and a member of the Audit Committee. The two join a strong, independent board with world-class talent and unique and differentiated skillsets.\n\"Both Steve and Scott collectively bring more than 30 years of experience in healthcare, and the appointments are part of our continual process to attract strong independent directors. We believe these two extremely talented business executives will help broaden the skills of the current Board, especially in the fields of corporate finance and international expansion, while bringing their expertise to foster adoption of transformative medical advances across the global marketplace,\" said Dr. Robert Epstein, Chair of the Nominating/Corporate Governance Committee. \"We welcome Steve and Scott to the board and look forward to working with them to drive profitable growth and shareholder value creation.\"\n\"Steve and Scott are highly respected business leaders whose public company experience and financial acumen will be very valuable to shareholders, customers and employees,\" said Francis deSouza, CEO of Illumina.\nIn addition, the Board nominated and elected independent director Sue Siegel to become Chair of Illumina's Compensation Committee, as Gary Guthart rotates off as Chair of the Compensation Committee.\nNew Independent Director Biographies\nStephen P. MacMillan\nSteve MacMillan joined Hologic in December 2013 as President and CEO, and has led a dram...